Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 205 of the 222 references it cites were found in a registry or an index; 39 of the 219 sources its claims cite were checked for support.
Abstract
OBJECTIVE: This clinical practice guideline addresses the diagnosis and treatment of primary adrenal insufficiency. PARTICIPANTS: The Task Force included a chair, selected by The Clinical Guidelines Subcommittee of the Endocrine Society, eight additional clinicians experienced with the disease, a methodologist, and a medical writer. The co-sponsoring associations (European Society of Endocrinology and the American Association for Clinical Chemistry) had participating members. The Task Force received no corporate funding or remuneration in connection with this review. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to determine the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: The evidence used to formulate recommendations was derived from two commissioned systematic reviews as well as other published systematic reviews and studies identified by the Task Force. The guideline was reviewed and approved sequentially by the Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee, members responding to a web posting, and the Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. CONCLUSIONS: We recommend diagnostic tests for the exclusion of primary adrenal insufficiency in all patients with indicative clinical symptoms or signs. In particular, we suggest a low diagnostic (and therapeutic) threshold in acutely ill patients, as well as in patients with predisposing factors. This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension. We recommend a short corticotropin test (250 μg) as the "gold standard" diagnostic tool to establish the diagnosis. If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels. Diagnosis of the underlying cause should include a validated assay of autoantibodies against 21-hydroxylase. In autoantibody-negative individuals, other causes should be sought. We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15-25 mg/d) or cortisone acetate replacement (20-35 mg/d) applied in two to three daily doses in adults. In children, hydrocortisone (∼8 mg/m(2)/d) is recommended. Patients should be educated about stress dosing and equipped with a steroid card and glucocorticoid preparation for parenteral emergency administration. Follow-up should aim at monitoring appropriate dosing of corticosteroids and associated autoimmune diseases, particularly autoimmune thyroid disease.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline provides evidence-based recommendations for diagnosing and treating primary adrenal insufficiency (PAI), emphasizing a low diagnostic threshold, the 250-µg short corticotropin test as the diagnostic gold standard, and glucocorticoid/mineralocorticoid replacement with adrenal crisis prevention. It also highlights major evidence gaps, including sparse randomized trial data for replacement regimens and limited diagnostic accuracy studies specifically in PAI.
Key findings
- For diagnosis, the guideline recommends testing patients with indicative symptoms/signs and using the standard-dose 250-µg corticotropin stimulation test as the “gold standard”; peak cortisol below 500 nmol/L (18 µg/dL) at 30 or 60 minutes indicates adrenal insufficiency. The high-dose ACTH stimulation test had a sensitivity of 92% (95% CI, 81–97%) for PAI based on five studies; no studies were available for the low-dose test in PAI. If corticotropin testing is not feasible, a morning cortisol <140 nmol/L (5 µg/dL) plus ACTH is suggested as a preliminary test.
- Autoimmune adrenalitis is the most common cause of PAI, accounting for up to 90% in Western countries; 21-hydroxylase autoantibodies should be measured, and about 30% of CYP21A2 autoantibody-positive individuals progressed to overt PAI during 5-year follow-up. In autoantibody-negative individuals, other causes should be sought, including adrenoleukodystrophy in males via very-long-chain fatty acids and adrenal CT for infiltrative or malignant disease.
- In adults, recommended replacement is hydrocortisone 15–25 mg/d or cortisone acetate 20–35 mg/d in two or three divided doses, with fludrocortisone starting at 50–100 µg/d (median, 0.1 mg) for confirmed aldosterone deficiency. Prednisolone 3–5 mg/d is an alternative, while dexamethasone is suggested against. DHEA replacement may be tried for 6 months in women with low libido, depressive symptoms, and/or low energy despite optimized replacement.
- For adrenal crisis, immediate parenteral hydrocortisone 100 mg (50 mg/m² for children) is recommended, followed by 200 mg/24 h (50–100 mg/m²/d for children), plus fluid resuscitation. Reported adrenal crisis frequencies were 6.6 crises/100 patient-years in a retrospective analysis of 444 patients and 8.3 crises/100 patient-years in a prospective study of 768 patient-years, with a crisis mortality rate of 0.5/100 patient-years.
Methods
- This is a GRADE-based clinical practice guideline developed by an Endocrine Society Task Force with a methodologist and medical writer; recommendations are graded strong (“we recommend,” 1) or weak (“we suggest,” 2), with evidence quality from QEEE (very low) to QQQQ (high), plus ungraded best practice statements.
- Evidence came from two commissioned systematic reviews and other published systematic reviews/studies. The first review compared high-dose vs low-dose ACTH stimulation for diagnosis and found only five studies for high-dose ACTH in PAI and none for low-dose ACTH in PAI. The second review compared glucocorticoid replacement regimens and identified 15 observational studies; mortality, bone density, and adrenal crisis data were very sparse or unavailable, and there was no statistically significant HRQoL difference between hydrocortisone dosages ≥30 mg/d vs <30 mg/d.
- The guideline was reviewed and approved sequentially by Endocrine Society committees, members responding to a web posting, and the Endocrine Society Council; the Task Force received no corporate funding or remuneration.
Limitations
- The paper states that the evidence base is limited: there are no randomized controlled trials for many treatment questions, diagnostic accuracy data for high-dose ACTH in PAI come from only five studies with none for low-dose ACTH in PAI, and the second systematic review found sparse or unavailable data on mortality, bone density, and adrenal crisis, with very low-quality evidence for extended-release/dual-release glucocorticoids. Many recommendations are weak or ungraded best practice statements.
- The paper states that cortisol cutoff values after corticotropin stimulation vary by assay, ACTH assays have analytical bias, and actual clinical cutpoints should be based on assay-specific normative data.
- Evident from the text: the guideline focuses only on PAI and explicitly excludes secondary adrenal insufficiency and critical illness-related corticosteroid insufficiency; some recommendations rely on clinical experience, unsystematic observations, and values/preferences rather than direct systematic evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the diagnostic approach to the patient with PAI. The most common causes of PAI are autoimmune destruction of the adrenal cortex in adults and CAH in children. These etiologies can be screened for using 21-hydroxylase antibodies and a baseline serum 17hydroxyprogesterone level. Males with negative 21-hydroxylase antibodies should be tested for adrenoleukodystrophy with plasma VLCFAs. If these diagnoses are excluded, a CT scan of the adrenals may reveal evidence of adrenal infiltrative processes or metastases. The individual's clinical picture and family history may render some steps in the algorithm redundant or suggest specific genetic syndromes. The latter includes subtypes of autoimmune polyglandular syndromes or specific rare genetic disorders where adrenal failure is part of a broader phenotype. A list of differential diagnoses is provided in Table 2. AHC, adrenal hypoplasia congenita; AI, adrenal insufficiency; VLCFA, very long chain fatty acid. a 17-OHprogesterone > 1000 ng/dL is diagnostic for 21-OH deficiency (14). b VLCFA should be measured in the initial evaluation of preadolescent boys. [Adapted from E. S. Husebye, et al: Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med . 2014;275:104-115 (181), with permission. © John Wiley & Sons, Inc.]](https://figures.cochat.ai/paper-figures/3d28d00e3ab049b5b513e655fd2f1f7a/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-figure-1.png)
Verification
Claims the paper makes
35 Valid · 2 Not valid · 109 Not checked · 48 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, in all these reports, adrenal crisis was a significant cause of death.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Disputedcites [149] 149. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: a pop- ulation-based study. J Clin Endocrinol Metab. 2006;91:4849 - 4853. sourceExperimental — accuracy not yet measured
The Mortality section reports 36 deaths attributed to adrenal insufficiency but explicitly says that no patient was reported to have died from adrenal crisis under ICD-10. It also cautions that ICD-9 cannot distinguish adrenal crisis from primary adrenal insufficiency, so the study does not establish crisis as a significant cause of death. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [150] 150. Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or com- bined autoimmune primary adrenocortical insufficiency. Clin En- docrinol (Oxf). 2008;69:697-704. source
- Not checked — no full text of the sourcecites [7] 7. Erichsen MM, Løvås K, Fougner KJ, et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of prema- ture death. Eur J Endocrinol. 2009;160:233-237. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition to a paired sample of cortisol and ACTH, the adrenal reserve is appropriately and safely assessed in pregnancy by corticotropin stimulation, if indicated (40,41).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Supportedcites [40] 40. Lebbe M, Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf). 2013;78:497-502. source
The Investigations section (p. 3) calls the short Synacthen test a valid measure of adrenal cortisol reserve, including in pregnancy, and says there is no medical reason to avoid a single diagnostic dose in a pregnant woman. The Summary (p. 1) recommends the test when clinically feasible, alongside paired cortisol and ACTH measurements. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [41] 41. Suri D, Moran J, Hibbard JU, Kasza K, Weiss RE. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab. 2006;91:3866 -3872. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Patients with diseases such as nephrotic syndrome (43) and liver disease (50) as well as those who are in the immediate postoperative period (51) or who require intensive care (52) may have lower CBG and albumin and hence, lower cortisol measurements.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Not checked — no full text of the sourcecites [43] 43. Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocri- nol Metab. 2007;92:1326 -1333. source
- Not checked — no full text of the sourcecites [50] 50. Vincent RP, Etogo-Asse FE, Dew T, Bernal W, Alaghband-Zadeh J, le Roux CW. Serum total cortisol and free cortisol index give different information regarding the hypothalamus-pituitary-adre- nal axis reserve in patients with liver impairment. Ann Clin Biochem. 2009;46:505-507. source
- Supportedcites [51] 51. le Roux CW, Chapman GA, Kong WM, Dhillo WS, Jones J, Alagh- band-Zadeh J. Free cortisol index is better than serum total cortisol in determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. J Clin Endocrinol Metab. 2003;88:2045- 2048. source
For the part attributed to this source—the immediate postoperative period—the Results report that albumin and CBG fell after surgery, and that seven patients had unexpectedly low postoperative total cortisol. The Discussion attributes those low cortisol values to the fall in CBG. The other conditions in the citing sentence have separate citations. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [52] 52. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350: 1629 -1638. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interpretation of the diagnostic results requires thorough consideration of pregnancy-associated physiological changes of adrenocortical function (42).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Supportedcites [42] 42. Jung C, Ho JT, Torpy DJ, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011;96:1533-1540. source
The Discussion (page not specified in the supplied passage) says that physiological hypercortisolism can be difficult to distinguish from Cushing’s syndrome during pregnancy and emphasizes trimester-specific reference ranges. This supports considering pregnancy-related adrenocortical changes when interpreting diagnostic results. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An elevated ACTH concentration in the presence of a cortisol in the normal range can be the first sign of early-stage PAI (68).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Could not verifycites [68] 68. Baker PR, Baschal EE, Fain PR, et al. Haplotype analysis discrim- inates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison's disease. J Clin Endo- crinol Metab. 2010;95:E263-E270. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that 21-hydroxylase autoantibodies usually precede overt Addison’s disease and proposes subsequent adrenal-function testing. Neither that passage nor the passages retrieved by searching for ACTH, cortisol, and early adrenal insufficiency addresses whether elevated ACTH with normal-range cortisol can be an early sign of PAI. (LLM, conf=0.73)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
118 more claims · 24 with their cited sources checked
Create a free account to see all 194 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 58
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In children, glucocorticoid replacement therapy (GCCrt) should be started with hydrocortisone (HC) at a total daily dose of 10 mg/m2, with dose titration according to individual needs (35).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“no drug suitably mimics the diurnal pattern of cortisol”
From Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells (2018) · cites this paper as Bornstein et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In such cases, a GC dosage increase of 20% to 40% from the 24th week onward is often beneficial (215).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [215]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, no consensus exists regarding the optimal dose and hydrocortisone delivery mode during major stress, and current recommendations are empirical rather than evidence-based (7, 17).”
From Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery (2020) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In primary and secondary adrenal insufficiency, peak cortisol levels < 500 nmol/L (< 18.1 μg/dL), depending on assay, are indicative of adrenal insufficiency (38, 39).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [38]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > 2.2
“We suggest the low-dose (1 g) corticotropin test for diagnosis of PAI only when the substance itself is in short supply.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
“Thus, for practical reasons, the low-dose test may be applicable to situations when corticotropin is in short supply or for other structural or economic reasons.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development of evidence-based guidelines (15).”
MethodSapolsky, R. M., Romero, L. M., & Munck, A. U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.1.0389 · Cited by 7,541 · cited 1×
“Enhanced glucocorticoid secretion in critical illness is considered necessary to prevent defense mechanisms (eg, cytokine release) from overshooting with concomitant detrimental toxicity (142, 143).”
BackgroundSapolsky, R. M. (2000) · Endocrine Reviews · doi:10.1210/er.21.1.55 · Cited by 7,533
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 1×
“In newborns and children, mineralocorticoid sensitivity is lower, thereby usually requiring higher fludrocortisone doses compared to adults (106).”
BackgroundSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 4×
“a 17-OHprogesterone 1000 ng/dL is diagnostic for 21-OH deficiency (14).”
BackgroundMethodInfluentialSelf-citationORENTREICH, N., BRIND, J. L., RIZER, R. L., & VOGELMAN, J. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-551 · Cited by 1,349 · cited 1×
“Serum DHEAS concentrations physiologically peak between ages 20 and 30 years, followed by a gradual decline that is independent of menopause (113).”
BackgroundSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCorticosteroid insufficiency in acutely ill patients
Cooper, M. S., & Stewart, P. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020529 · Cited by 1,033
Marik, P. E., Pastores, S. M., Annane, D., Meduri, G. U., Sprung, C. L., Arlt, W., Keh, D., Briegel, J., Beishuizen, A., Dimopoulou, I., et al. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31817603ba · Cited by 912 · cited 1×
“Although similar arguments for the utility of the low-dose test have been proposed for other special diagnostic challenges such as the detection of adrenal insufficiency in critically ill patients (critical illness-related corticosteroid insufficiency), more evidence is needed to support such a formal recommendation (…”
BackgroundSelf-citationPharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 1×
“Because of the short plasma half-life of hydrocortisone (approximately 90 min) (90), multiple dosing is recommended to mimic physiological conditions.”
Background
Research works printed but not linked: 3
- [29]29. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insuffi- ciency. Ann Intern Med. 2003;139:194 -204.
- [110]110. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on miner- alocorticoid replacement with fludrocortisone in adrenal insuffi- ciency. Am J Med Sci. 1986;291:280 -283.
- [177]177. Gan EH, MacArthur K, Mitchell AL, et al. Residual adrenal func- tion in autoimmune Addison's disease: improvement after tetra- cosactide (ACTH1-24) treatment. J Clin Endocrinol Metab. 2014; 99:111-118.
Cited by
Items 401–500 of 1,752
Elder, C. J., Vilela, R., Johnson, T. N., Taylor, R. N., Kemp, E. H., Keevil, B. G., Cross, A. S., Ross, R. J. M., & Wright, N. P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa323 · Cited by 17
Rabijewski, M., Papierska, L., Bińkowska, M., Maksym, R., Jankowska, K. K., Skrzypulec‐Plinta, V., & Zgliczyński, W. (2020) · Ginekologia Polska · doi:10.5603/gp.2020.0091 · Cited by 21
Pharmacological and analytical interference in hormone assays for diagnosis of adrenal incidentaloma
Lopez, A.-G., Fraissinet, F., Lefèbvre, H., Brunel, V., & Ziegler, F. (2019) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.11.006 · Cited by 15
Melin, J., Hartung, N., Parra‐Guillen, Z. P., Whitaker, M. J., Ross, R. J., & Kloft, C. (2019) · Clinical Endocrinology · doi:10.1111/cen.13969 · Cited by 15
A Rare Case of Autoimmune Polyglandular Syndrome Type 2 in a Child With Persistent Fatigue
Smith, R. K., & Gerrits, P. (2019) · Global Pediatric Health · doi:10.1177/2333794x19845074 · Cited by 15
Evaluating the Low-Dose ACTH Stimulation Test in Neonates: Ideal Times for Cortisol Measurement
LeDrew, R. L., Bariciak, E., Webster, R. J., Barrowman, N., & Ahmet, A. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa635 · Cited by 16
Adrenoleukodystrophy in the era of newborn screening
Eng, L., & Regelmann, M. O. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000515 · Cited by 20
The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors
Mai, K., Faßnacht, M., Führer‐Sakel, D., Honegger, J. B., Weber, M. M., & Kroiß, M. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0143 · Cited by 17
Novel methods in adrenal research: a metabolomics approach
Papathomas, T. G., Sun, N., Chortis, V., Taylor, A. E., Arlt, W., Richter, S., Eisenhofer, G., Ruiz-Babot, G., Guasti, L., & Walch, A. K. (2019) · Histochemistry and Cell Biology · doi:10.1007/s00418-019-01772-w · Cited by 14
Self-citationArlt, W., de la Perrière, A. B., Hirschberg, A. L., Merke, D. P., Newell-Price, J. D. C., Prete, A., Rees, A., Reisch, N., Touraine, P. A., Bendfeldt, H., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf130 · Cited by 19
Self-citationUpdate and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome
Araujo-Castro, M., Lamas, C., Nowak, E., Newell-Price, J. D. C., Reincke, M., & Castinetti, F. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf042 · Cited by 24
Guarnotta, V., Stefano, C. D., & Giordano, C. S. D. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13506-5 · Cited by 17
Transition Readiness in Adolescents and Young Adults Living With Congenital Adrenal Hyperplasia
Ekbom, K., Lajić, S., Falhammar, H., & Nordenström, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.01.010 · Cited by 17
The dynamics of a serum steroid profile after stimulation with intravenous ACTH
Lindner, J. M., Suhr, A. C., Grimm, S., Möhnle, P., Vogeser, M., & Briegel, J. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.12.045 · Cited by 13
Chao, C. S., Shi, R., Kumar, R. B., & Aye, T. (2019) · Endocrine · doi:10.1007/s12020-019-02084-8 · Cited by 16
Cadegiani, F., & Kater, C. E. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0443-7 · Cited by 20
Should Pediatric Endocrinologists Consider More Carefully When to Perform a Stimulation Test?
Penco, A., Bossini, B., Giangreco, M., Vidonis, V., Vittori, G., Grassi, N., Pellegrin, M. C., Faleschini, E., Barbi, E., & Tornese, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.660692 · Cited by 15
Current and future treatment options for adrenal insufficiency
Arshad, M. F., & Debono, M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000637 · Cited by 13
“Hydrocortisone and cortisone are the first choice of glucocorticoids to treat AI in accordance with clinical guidelines [27], though hydrocortisone is much more frequently used in most countries.”
BackgroundThe Adrenal Cortex and Its Disorders
Miller, W. L., Flück, C. E., Breault, D. T., & Feldman, B. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00014-2 · Cited by 37
Adrenal Crisis Secondary to COVID-19 Vaccination in a Patient With Hypopituitarism
Markovic, N., Faizan, A., Boradia, C., & Nambi, S. (2022) · AACE Clinical Case Reports · doi:10.1016/j.aace.2022.04.004 · Cited by 15
Matejek, N., Hoos, J. S., Holterhus, P., Bettendorf, M., & Choukair, D. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03659-2 · Cited by 19
“If CS is obvious and iatrogenic adrenal insufficiency is induced, abrupt discontinuation of long-standing glucocorticoid treatment should be avoided [3, 25].”
BackgroundInhaled corticosteroids and HPA axis suppression: how important is it and how should it be managed?
Bondugulapati, L. N. R., & Rees, A. (2016) · Clinical Endocrinology · doi:10.1111/cen.13073 · Cited by 16
Testosterone replacement therapy: role of pituitary and thyroid in diagnosis and treatment
Crawford, M., & Kennedy, L. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.09.01 · Cited by 17
Tirosh, A., Papadakis, G. E., Chittiboina, P., Lyssikatos, C., Belyavskaya, E., Keil, M. F., Lodish, M. B., & Stratakis, C. A. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-107245 · Cited by 14
Self-citationWagmode, N., Mathew, V., Bantwal, G., Ayyar, V. S., George, B., Patanjali, C., & Michael, J. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_114_18 · Cited by 13
Glucocorticoids with or without Fludrocortisone in Septic Shock
Venkatesh, B., Finfer, S. R., & Myburgh, J. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1804993 · Cited by 16
Arafah, B. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa042 · Cited by 13
Guaraldi, F., Gori, D., Calderoni, P., Castiello, E., Pratelli, L., Leporati, M., Arvat, E., & Battaglia, M. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01033-6 · Cited by 13
Edelman, S. V., Agardh, D., Cui, N., Hao, L., Wieloch, M., & Meneghini, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16454 · Cited by 21
“31 Additionally, despite the American Diabetes Association (ADA) guidelines mentioning that individuals with a family or personal history of other related autoimmune diseases are at increased risk of developing T1D compared to the general population, the most recent guidelines provide no…”
Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?
Čechová, A., Honzík, T., Edmondson, A. C., et al. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.06.003 · Cited by 13
“To account for inter- and intra-assay variation and random times of morning collection [5–7] we classified subjects to be at-risk for central AI (CAI) and in need of confirmatory testing those with a cortisol below5 μg/dL in combinationwith a normal or belownormal ACTH level, dependent on the respective normative rang…”
MethodBioletto, F., Berton, A. M., Varaldo, E., Cuboni, D., Bona, C., Parasiliti‐Caprino, M., Prencipe, N., Ghigo, E., Grottoli, S., Maccario, M., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01926-z · Cited by 13
Adrenal crisis in infants and young children with adrenal insufficiency: Management and prevention
Bizzarri, C., Capalbo, D., Wasniewska, M. G., Baronio, F., Grandone, A., & Cappa, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1133376 · Cited by 13
Bouki, K., Venetsanaki, V., Chrysoulaki, M., Pateromichelaki, A., Betsi, G., Daraki, V. N., Sbyrakis, N., Spanakis, K., Bertsias, G. K., Sidiropoulos, P. I., et al. (2023) · HORMONES · doi:10.1007/s42000-023-00463-5 · Cited by 18
“Oligo-amenorrhea may be due to chronic illness, weight loss, or autoimmune primary ovarian insufficiency [7].”
BackgroundInfluentialAdrenal Crisis – Definition, Prevention and Treatment: Results from a Delphi Survey
Kienitz, T., Bechmann, N., Deutschbein, T., Hahner, S., Honegger, J. B., Kroiß, M., Quinkler, M. O., Rayes, N., Reisch, N., Willenberg, H. S., et al. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2130-1938 · Cited by 16
“In man - agement of adrenal crisis, surgery that requires general anesthesia, trauma or delivery our expert panel largely agrees with current recommendations ( ▶ Table 2 ) [17, 18].”
Endocrine immune-related adverse effects of immune-checkpoint inhibitors
Trevisani, V., Iughetti, L., Lucaccioni, L., & Predieri, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256841 · Cited by 18
Evaluation and follow-up of patients diagnosed with hypophysitis: a cohort study
Hacıoğlu, A., Karaca, Z., Uysal, S., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae101 · Cited by 13
Generating method-specific Reference Ranges – A harmonious outcome?
Lee, G. R., Griffin, A., Halton, K., & Fitzgibbon, M. C. (2017) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2017.06.001 · Cited by 15
Health maintenance for adults with neuromuscular diseases on immunosuppression
Cartwright, S. L., & Cartwright, M. S. (2018) · Muscle & Nerve · doi:10.1002/mus.26382 · Cited by 13
Triple-A Syndrome (TAS): An In-Depth Overview on Genetic and Phenotype Heterogeneity
Pogliaghi, G., Cangiano, B., Duminuco, P., Vezzoli, V., & Bonomi, M. (2020) · Protein and Peptide Letters · doi:10.2174/0929866527666200613215449 · Cited by 17
Risk Factors and Management of Leukopenia After Kidney Transplantation: A Single-Center Experience
Henningsen, M., Jaenigen, B., Zschiedrich, S., Pisarski, P., Walz, G., & Schneider, J. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.04.011 · Cited by 14
Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic
Barnabei, A., Senes, P., Scoppola, A., Chiefari, A., Iannantuono, G. M., Appetecchia, M., & Torino, F. (2022) · Cancers · doi:10.3390/cancers14030593 · Cited by 14
“1 mg to reduce at the onset of arterial hypertension [21].”
BackgroundWentworth, B. J., Schliep, M. K., Novicoff, W. M., Siragy, H. M., Geng, C. X., & Henry, Z. H. (2022) · Liver International · doi:10.1111/liv.15473 · Cited by 15
Zhang, Y., Wang, J., Hu, T., Wang, H., Long, M., & Liang, B. (2022) · Life · doi:10.3390/life12121990 · Cited by 15
“Once patients are diagnosed with adrenal insufficiency, it can be so serious that hospitalization is required [41].”
BackgroundHelderman, N. C., Lucas, M. W., & Blank, C. U. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100374 · Cited by 13
Screening for primary aldosteronism using the newly developed IDS-iSYS® automated assay system
O’Shea, P. M., Griffin, T. P., Browne, G. A., Gallagher, N., Brady, J. J., Dennedy, M. C., Bell, M., Wall, D., & Fitzgibbon, M. C. (2016) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2016.11.002 · Cited by 13
Self-management in adrenal insufficiency — towards a better understanding
Kampmeyer, D., Haas, C. S., Moenig, H., & Harbeck, B. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0429 · Cited by 18
Adrenal Insufficiency in Cirrhosis Patients: Evaluation of 108 Case Series
Rakıcı, H. (2016) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1237 · Cited by 13
de Heide, L. J. M., de Boer, H. H. R., van Borren, M. M. G. J., Emous, M., Aarts, E. O., & de Boer, H. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00239 · Cited by 13
Accuracy of hydrocortisone dose administration via nasogastric tube
Daniel, E., Whitaker, M. J., Keevil, B. G., Wales, J. K., & Ross, R. J. M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13876 · Cited by 16
Wang, D., Li, H., Zhang, Y., Wang, L., & Ji, Z. (2018) · Surgical Laparoscopy Endoscopy & Percutaneous Techniques · doi:10.1097/sle.0000000000000585 · Cited by 15
Hyponatraemia and hyperpigmentation in primary adrenal insufficiency
Benner, B. J. M., Alsma, J., & Feelders, R. A. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-227200 · Cited by 13
Endocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13
The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism
Choudhury, S., Tan, T., Lazarus, K., & Meeran, K. M. (2021) · Endocrine Connections · doi:10.1530/ec-20-0473 · Cited by 17
Impaired attention in patients with adrenal insufficiency – Impact of unphysiological therapy
Blacha, A. K., Rahvar, A., Flitsch, J., van de Loo, I., Kropp, P. A., & Harbeck, B. (2021) · Steroids · doi:10.1016/j.steroids.2020.108788 · Cited by 17
“State of the art is 15–25 mg hydrocortisone (HC) applied in two or three doses daily with the highest dose in the morning [3].”
BackgroundDelle Cese, F., Corsello, A., Cintoni, M., Locantore, P., Pontecorvi, A., Corsello, S. M., & Paragliola, R. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.610904 · Cited by 13
Anesthetic management during transsphenoidal pituitary surgery
Esfahani, K., & Dunn, L. K. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001035 · Cited by 13
“Those with a normally functioning hypothalamic–pituitary–adrenal axis do not require perioperative steroid therapy when undergoing endoscopic pituitary adenoma resection [5].”
BackgroundLin, W., Huang, H., Wen, J., Wang, N., Wang, S.-Y., Wang, C., & Chen, G. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.94 · Cited by 14
Kawahara, T., Tsuji, M., Tominaga, N., Toyama, N., & Toda, M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac119 · Cited by 13
“In accordance with the guidelines [10, 21, 33], administration of hydrocortisone to our AI patients promptly improved their hypoglycemia, and glucose administration was no longer necessary.”
BackgroundArshad, M. F., Elder, C., Newell-Price, J., Ross, R., & Debono, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae059 · Cited by 12
Rare forms of genetic paediatric adrenal insufficiency: Excluding congenital adrenal hyperplasia
Hasenmajer, V., Ferrigno, R., Minnetti, M., Pellegrini, B., Isidori, A. M., Lenzi, A., Salerno, M., Cappa, M., Chan, L. F., Martino, M. C. D., et al. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09784-7 · Cited by 24
Approach to the Patient: Diagnosis of Primary Adrenal Insufficiency in Adults
Øksnes, M., & Husebye, E. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad402 · Cited by 21
Self-citationEl‐Farhan, N., Tennant, S., Rees, S. E., Evans, C., & Rees, A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad576 · Cited by 17
Approach to the Patient With Bilateral Adrenal Masses
Vassiliadi, D. A., Delivanis, D. A., Papalou, O., & Tsagarakis, S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae164 · Cited by 16
Primary adrenal insufficiency in adults: When to suspect, how to diagnose and manage
Lundholm, M. D., Ambalavanan, J., & Rao, P. P. R. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23072 · Cited by 14
Kamrath, C., Hartmann, M. F., & Wudy, S. A. (2019) · Steroids · doi:10.1016/j.steroids.2019.108426 · Cited by 13
Supportive medication in cancer during pregnancy
Zagouri, F., Dedes, N., Papatheodoridi, A. M., Liontos, M., & Dimopoulos, M. A. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-03432-7 · Cited by 16
Blacha, A. K., Kropp, P. A., Rahvar, A., Flitsch, J., van de Loo, I., & Harbeck, B. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02731-y · Cited by 12
“The fact that patients with PAI showed worse results in AddiQoL than those with SAI is plausible due to the diseasespecific design of this questionnaire [22, 26].”
InfluentialGuarnotta, V., Amodei, R., & Giordano, C. S. D. S. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.003 · Cited by 14
Westeinde, A. V., Ström, S., Hirvikoski, T., Dahlqvist, P. M., Wahlberg, J., Gezelius, A., Kämpe, O., Bensing, S., & Lajić, S. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105714 · Cited by 13
Reducing the off-target endocrinologic adverse effects of azole antifungals—can it be done?
Balcerek, M. I., Stewart, A. G., Chapman, P. R., & Lazarus, S. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106587 · Cited by 16
Brugada phenocopy secondary to hyperkalemia and hyponatremia in primary adrenal insufficiency
Amusina, O., Mehta, S., & Nelson, M. E. (2022) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12800 · Cited by 12
Beun, J. G., Burman, P., Kämpe, O., Husebye, E. S., Hahner, S., Kristensen, J. K., Noordzij, A., & Dahlqvist, P. M. (2022) · Endocrine Connections · doi:10.1530/ec-22-0345 · Cited by 16
Self-citationUtari, A., Faradz, S. M., Ediati, A., Rinne, T., Ariani, M. D., Juniarto, A. Z., Drop, S. L. S., van Herwaarden, A. E., & der Grinten, H. L. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1015973 · Cited by 17
Valerio, L., Giani, C., Matrone, A., Contillo, B. P., Minaldi, E., Agate, L., Molinaro, E., & Elisei, R. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02025-3 · Cited by 13
“The diagnosis of AI was defined by a blunted peak of cortisol < 18 μg/dL at 30 or 60 min, associated, in some cases, with elevated basal serum ACTH levels [18].”
BackgroundMethodResultInfluentialGroup 3: Strategies for identifying the cause of adrenal insufficiency: diagnostic algorithms
Proust-Lemoine, E., Reynaud, R., Delemer, B., Tabarin, A., & Samara‐Boustani, D. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.006 · Cited by 12
Guignat, L., Proust-Lemoine, E., Reznik, Y., & Zénaty, D. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.009 · Cited by 11
Ghajar, L. D., Heickman, L. K. W., Conaway, M. R., & Rogol, A. D. (2019) · Clinical Pediatrics · doi:10.1177/0009922818825154 · Cited by 12
Albert, L., Profitós, J., Sánchez‐Delgado, J., Capel, I., González-Clemente, J. M., Subías, D., Cano, A., Berlanga, E., Espinal, A., Hurtado, M., et al. (2019) · International Journal of Endocrinology · doi:10.1155/2019/7251010 · Cited by 12
Renal involvement in adrenal insufficiency (Addison disease): can we always recognize it?
Fofi, C., Maresca, B., Altieri, S., Mené, P., & Festuccia, F. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02209-x · Cited by 14
Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review
Mongioì, L. M., Condorelli, R. A., Barbagallo, F., Vignera, S. L., & Calogero, A. E. (2020) · Endocrine · doi:10.1007/s12020-020-02187-7 · Cited by 15
Three cases of 3β-hydroxysteroid dehydrogenase deficiency: Clinical analysis
Chen, L., Huang, H., Zhang, H., Zhu, G., & Zhu, M. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/131220 · Cited by 16
Ngaosuwan, K., Johnston, D. G., Godsland, I. F., Cox, J., Majeed, A., Quint, J. K., Oliver, N. S., & Robinson, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab347 · Cited by 14
Malone, A. M. D., Price, J., Price, N., Peck, V., Getgood, A. M. J., Petrella, R. J., & Helliwell, J. (2021) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2021.100213 · Cited by 13
Jia, X., Pendharkar, A. V., Loftus, P., Dodd, R. L., Chu, O., Fraenkel, M., & Katznelson, L. (2016) · Endocrine Practice · doi:10.4158/ep161256.or · Cited by 12
Annane, D., Pastores, S. M., Rochwerg, B. N., Arlt, W., Ra, B., Beishuizen, A., Briegel, J., Carcillo, J. A., Christ‐Crain, M., Cooper, M. S., et al. (2018) · Yearbook of pediatric endocrinology · doi:10.1530/ey.15.8.10 · Cited by 12
Self-citationThe Adrenal Cortex and Its Disorders
Hughes, C. R., Man, E., & Achermann, J. C. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch9 · Cited by 19
Brain structure in autoimmune Addison’s disease
Westeinde, A. V., Padilla, N., Sanchez, M. S., Fletcher‐Sandersjöö, S., Kämpe, O., Bensing, S., & Lajić, S. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac389 · Cited by 12
“Androgens are not replaced as part of the standard treatment but may sometimes be given to women (Bornstein et al. 2016).”
BackgroundCortisol: Analytical and clinical determinants
Vega‐Beyhart, A., Castro, M. A., Hanzu, F. A., & Casals, G. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.11.005 · Cited by 14
Kibirige, D., Owarwo, N. C., Kyazze, A. P., Morgan, B., Olum, R., Bongomin, F., & Biraro, I. A. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae098 · Cited by 15
“…patients who are critically ill with tuberculosis (TB) or HIV poses a significant clinical challenge because it presents with nonspecific and subtle signs and symptoms, such as fatigue, weight loss, abdominal pain, nausea, vomiting, and myalgias, which often overlap with those of TB or HIV [1, 2].”
BackgroundUtility of Salivary Cortisol and Cortisone in the Diagnostics of Adrenal Insufficiency
Hellan, K. K., Lyngstad, M., Methlie, P., Løvås, K., Husebye, E. S., & Ueland, G. Å. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae486 · Cited by 14
Self-citationAuer, M. K., Minea, C. E., Quinkler, M. O., Bancos, I., Beuschlein, F., Meyer, G., Lottspeich, C., Bidlingmaier, M., Rieger, E., Nowotny, H. F., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae211 · Cited by 14
“All women in our cohort who had spontaneous abortion during their first pregnancy were taking a GC. GC dosage was not increased in all women during pregnancy as recommended [35] and the increase of median 4 mg in HCeq was only significant in women with NC CAH.”
Continuous subcutaneous hydrocortisone infusion in a woman with secondary adrenal insufficiency
Cardini, F., Torlone, E., Bini, V., & Falorni, A. (2018) · Endocrine · doi:10.1007/s12020-018-1780-4 · Cited by 11
Wood, L. S. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.2.13 · Cited by 15
Jingushi, N., Tsuzuki, S., Fujii, K., Uenishi, N., Iwata, M., & Terasawa, T. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.03.010 · Cited by 11
Yoo, H. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2142150.075 · Cited by 12
Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19
Sabbadin, C., Betterle, C., Scaroni, C. M., & Ceccato, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.805647 · Cited by 13
Krašovec, T., Šikonja, J., Tanšek, M. Ž., Debeljak, M., Ilovar, S., Podkrajšek, K. T., Bertok, S., Tesovnik, T., Kovač, J., Omladič, J. Š., et al. (2022) · Genes · doi:10.3390/genes13050717 · Cited by 13
“The recommended daily hydrocortisone dose in pediatric patients with PAI is 7–12 mg/m2, with a starting dose of 8 mg/m2, which is given in three divided doses [14,25,26].”
BackgroundMethodAdrenal insufficiency in pregnancy: Physiology, diagnosis, management and areas for future research
Lee, J. H., & Torpy, D. J. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09745-6 · Cited by 13
“Increasing the hydrocortisone dose by 20–40% from 24 weeks gestation onward is a common approach [59].”
BackgroundMethodInfluentialSelf-citationVitamin D and adrenal gland: Myth or reality? A systematic review
Refaie, A. F. A., Baldassini, L., Vita, M. D., Gonnelli, S., & Caffarelli, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1001065 · Cited by 15
Mortensen, M. L., Ørnstrup, M. J., & Gravholt, C. H. (2023) · International Journal of Endocrinology · doi:10.1155/2023/5315059 · Cited by 13
Metadata
- Authors
- Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., & Torpy, D. J.
- Affiliations
- King's College London (GB)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Royal Adelaide Hospital (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-02
- Volume
- 101
- Issue
- 2
- Pages
- 364-389
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4880116
- OpenAlex
- W2234917292
- Cited by
- 1,769
- References
- 222
- Citations by year
- 2026: 187 · 2025: 198 · 2024: 180 · 2023: 191 · 2022: 180 · 2021: 206 · 2020: 165 · 2019: 149 · 2018: 148 · 2017: 102 · 2016: 54
- FWCI
- 151.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by-nc-nd)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by-nc-nd)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- European Society of Endocrinology
- Novo Nordisk Fonden (NNF14OC0011005)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK062027)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- Addison's disease, diagnosis, hydrocortisone replacement, fludrocortisone, corticosteroid dose, stress dosing, 21-hydroxylase autoantibodies, autoimmune thyroid disease, pregnancy, glucocorticoid therapy, autoimmune adrenal insufficiency
- MeSH terms
- Adrenal Insufficiency, Female, Humans, Pregnancy, Societies, Medical, Evidence-Based Medicine, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.